News

17 September 2019

Mariona Graupera, Gabriela Jiménez Valerio, Bárbara Rivera Polo

  • Càncer

Three IDIBELL researchers receive "la Caixa" Banking Foundation grants to carry out pioneering research projects with great social impact

Researchers Mariona Graupera, Gabriela Jiménez Valerio and Bárbara Rivera Polo of the Bellvitge Biomedical Research Institute (IDIBELL) have been awarded three grants of the "Scholarships and Grants for Research and Innovation 2019" program of the banking Foundation "la Caixa", which were officia

17 September 2019
  • Neurociències

Children's brain recovers from stroke and acquires language abilities thanks to its plasticity

When adults suffer cerebral strokes that affect the left hemisphere and, specifically, a structure called arcuate fascicle, they generally lose their language skills and recover them with difficulty, if they do it.

16 September 2019

Dr Lourdes Farré, Dr Sònia Guil and PhD fellow Cristina Oliveira

  • Càncer

Discovered a molecule that regulates the development of cancer in a variety of human tumors

Drs Lourdes Farré, of the chemoresistance research group of ProCURE (Bellvitge Biomedical Research Institute – Catalan Institute of Oncology) and Sonia Guil, leader of the Regulatory and Chromatin RNA group of Josep Carreras Leukemia Research Institute, lead a study that identifies an intermediat

13 September 2019
  • Càncer

"We save lives" looks for heroes at Bellvitge's ‘festa major’

On the occasion of the ‘festa major’ of Bellvitge, an annual celebration which takes place in this district of L’Hospitalet from September 7 to 15, researchers of the Oncobell program of the Bellvitge  Biomedical Research Institute (IDIBELL) present the #josalvovides fundraising campaign for

12 September 2019

Grup de recerca TGF-beta i càncer (IDIBELL-Oncobell)

  • Càncer

An IDIBELL study offers new possibilities for personalized medicine to treat a prevalent type of liver cancer

Hepatocellular carcinoma (HCC) is one of the most common liver tumors, and its prevalence is increasing rapidly. It also presents a high frequency of relapse and risk of metastasis.